Hepatocyte Growth Factor Activator Inhibitor 2/Placental Bikunin (HAI-2/PB) Gene Is Frequently Hypermethylated in Human Hepatocellular Carcinoma

Cancer Research

Volumn 63, Issue 24, 2003, Pages 8674-8679

  Fukai, Kenichi ^a   Yokosuka, Osamu ^a   Chiba, Tetsuhiro ^a   Hirasawa, Yuichi ^a   Tada, Motohisa ^a   Imazeki, Fumio ^a   Kataoka, Hiroaki ^b   Saisho, Hiromitsu ^a  

^a CHIBA UNIVERSITY   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5-AZA-2'-DEOXYCYTIDINE; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; BISULFITE; DRUG DERIVATIVE; GENE PRODUCT; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 2; MEMBRANE PROTEIN; PLACENTAL BIKUNIN; SOYBEAN TRYPSIN INHIBITOR; SPINT2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CELL DIVISION; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DNA MICROARRAY; DNA SEQUENCE; DRUG EFFECT; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE INDUCTION; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER TUMOR; PATHOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LIVER NEOPLASMS; MEMBRANE GLYCOPROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TRYPSIN INHIBITOR, KUNITZ SOYBEAN;

EID: 0346059603     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Li, E., Bestor, T. H., and Jaenisch, R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell, 69: 915-926, 1992.
2. Okano, M., Bell, D. W., Haber, D. A., and Li, E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell, 99: 247-257, 1999.
3. Riggs, A. D., and Pfeifer, G. P. X-chromosome inactivation and cell memory. Trends Genet., 8: 169-174, 1992.
4. Li, E., Beard, C., and Jaenisch, R. Role for DNA methylation in genomic imprinting. Nature (Lond.), 366: 362-365, 1993.
5. Jones, P. A., and Laird, P. W. Cancer epigenetics comes of age. Nat. Genet., 21: 163-167, 1999.
6. Baylin, S. B., and Herman, J. G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet., 16: 168-174, 2000.
7. Esteller, M., Corn, P. G., Baylin, S. B., and Herman, J. G. A gene hypermethylation profile of human cancer. Cancer Res., 61: 3225-3229, 2001.
8. Costello, J. F., Fruhwald, M. C., Smiraglia, D. J., Rush, L. J., Robertson, G. P., Gao, X., Wright, F. A., Feramisco, J. D., Peltomaki, P., Lang, J. C., Schuller, D. E., Yu, L., Bloomfield, C. D., Caligiuri, M. A., Yates, A., Nishikawa, R., Su Huang, H., Petrelli, N. J., Zhang, X., O'Dorisio, M. S., Held, W. A., Cavenee, W. K., and Plass, C. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet., 24: 132-138, 2000.
9. Kanai, Y., Ushijima, S., Hui, A. M., Ochiai, A., Tsuda, H., Sakamoto, M., and Hirohashi, S. The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int. J. Cancer, 71: 355-359, 1997.
10. Liew, C. T., Li, H. M., Lo, K. W., Leow, C. K., Chan, J. Y., Hin, L. Y., Lau, W. Y., Lai, P. B., Lim, B. K., Huang, J., Leung, W. T., Wu, S., and Lee, J. C. High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene, 18: 789-795, 1999.
11. Yoshikawa, H., Matsubara, K., Qian, G. S., Jackson, P., Groopman, J. D., Manning, J. E., Harris, C. C., and Herman, J. G. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet., 28: 29-35, 2001.
12. Iwata, N., Yamamoto, H., Sasaki, S., Itoh, F., Suzuki, H., Kikuchi, T., Kaneto, H., Iku, S., Ozeki, I., Karino, Y., Satoh, T., Toyota, J., Satoh, M., Endo, T., and Imai, K. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene, 19: 5298-5302, 2000.
13. Kataoka, H., Shimomura, T., Kawaguchi, T., Hamasuna, R., Itoh, H., Kitamura, N., Miyazawa, K., and Koono, M. Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J. Biol. Chem., 275: 40453-40462, 2000.
14. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
15. Bachman, K. E., Herman, J. G., Corn, P. G., Merlo, A., Costello, J. F., Cavenee, W. K., Baylin, S. B., and Graff, J. R. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res., 59: 798-802, 1999.
16. Yano, N., Habib, N. A., Fadden, K. J., Yamashita, H., Mitry, R., Jauregui, H., Kane, A., Endoh, M., and Rifai, A. Profiling the adult human liver transcriptome: analysis by cDNA array hybridization. J. Hepatol., 35: 178-186, 2001.
17. Frizell, E., Liu, S. L., Abraham, A., Ozaki, I., Eghbali, M., Sage, E. H., and Zern, M. A. Expression of SPARC in normal and fibrotic livers. Hepatology, 21: 847-854, 1995.
18. Nakamura, Y., Handa, K., Iwamoto, R., Tsukamoto, T., Takahasi, M., and Mekada, E. Immunohistochemical distribution of CD9, heparin binding epidermal growth factor-like growth factor, and integrin α3β1 in normal human tissues. J. Histochem. Cytochem., 49: 439-444, 2001.
19. Malizia, G., Brunt, E. M., Peters, M. G., Rizzo, A., Broekelrnann, T. J., and McDonald, J. A. Growth factor and procollagen type I gene expression in human liver disease. Gastroenterology, 108: 145-156, 1995.
20. Hageman, G. S., Mullins, R. F., Russell, S. R., Johnson, L. V., and Anderson. D. H. Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells. FASEB J., 13: 477-484, 1999.
21. Kawaguchi, T., Qin, L., Shimomura, T., Kondo, J., Matsumoto, K., Denda, K., and Kitamura, N. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J. Biol. Chem., 272: 27558-27564, 1997.
22. Miyazawa, K., Shimomura, T., Kitamura, A., Kondo, J., Morimoto, Y., and Kitamura, N. Molecular cloning and sequence analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J. Biol. Chem., 268: 10024-10028, 1993.
23. Marlor, C. W., Delaria, K. A., Davis, G., Muller, D. K., Greve, J. M., and Tamburini, P. P. Identification and cloning of human placental bikunin, a novel serine protease inhibitor containing two Kunitz domains. J. Biol. Chem., 272: 12202-12208, 1997.
24. Delaria, K. A., Muller, D. K., Marlor, C. W., Brown, J. E., Das, R. C., Roczniak, S. O., and Tamburini, P. P. Characterization of placental bikunin, a novel human serine protease inhibitor. J. Biol. Chem., 272: 12209-12214, 1997.
25. Hamasuna, R., Kataoka, H., Meng, J. Y., Itoh, H., Moriyama, T., Wakisaka, S., and Koono, M. Reduced expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin (HAI-2/PB) in human glioblastomas: implication for anti-invasive role of HAI-2/PB in glioblastoma cells. Int. J. Cancer, 93: 339-345, 2001.
26. Nakamura, T., Nawa, K., Ichihara, A., Kaise, N., and Nishino, T. Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett., 224: 311-316, 1987.
27. Gohda, E., Tsubouchi, H., Nakayama, H., Hirono, S., Sakiyama, O., Takahashi, K., Miyazaki, H., Hashimoto, S., and Daikuhara, Y. Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J. Clin. Investig., 81: 414-419, 1988.
28. Rosen, E. M., Nigam, S. K., and Goldberg, I. D. Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction. J. Cell Biol., 127: 1783-1787, 1994.
29. Boros, P., and Miller, C. M. Hepatocyte growth factor: a multifunctional cytokine. Lancet, 345: 293-295, 1995.
30. Matsumoto, K., and Nakamura, T. Emerging multipotent aspects of hepatocyte growth factor. J. Biochem. (Tokyo), 119: 591-600, 1996.
31. Shiota, G., Rhoads, D. B., Wang, T. C., Nakamura, T., and Schmidt, E. V. Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells. Proc. Natl. Acad. Sci. USA, 89: 373-377, 1992.
32. Santoni-Rugiu, E., Preisegger, K. H., Kiss, A., Audolfsson, T., Shiota, G., Schmidt, E. V., and Thorgeirsson, S. S. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Proc. Natl. Acad. Sci. USA, 93: 9577-9582, 1996.
33. Sakata, H., Takayama, H., Sharp, R., Rubin, J. S., Merlino, G., and LaRochelle, W. J. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ., 7: 1513-1523, 1996.
34. Bell, A., Chen, Q., DeFrances, M. C., Michalopoulos, G. K., and Zarnegar, R. The five amino acid-deleted isoform of hepatocyte growth factor promotes carcinogenesis in transgenic mice. Oncogene, 18: 887-895, 1999.
35. Horiguchi, N., Takayama, H., Toyoda, M., Otsuka, T., Fukusato, T., Merlino, G., Takagi, H., and Mori, M. Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene, 21: 1791-1799, 2002.
36. Prat, M., Narsimhan, R. P., Crepaldi, T., Nicotra, M. R., Natali, P. G., and Comoglio, P. M. The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int. J. Cancer, 49: 323-328, 1991.
37. Boix, L., Rosa, J. L., Ventura, F., Castells, A., Bruix, J., Rodes, J., and Bartrons, R. c-met mRNA overexpression in human hepatocellular carcinoma. Hepatology, 19: 88-91, 1994.
38. Ueki, T., Fujimoto, J., Suzuki, T., Yamamoto, H., and Okamoto, E. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology, 25: 619-623, 1997.
39. Shiota, G., Okano, J., Kawasaki, H., Kawamoto, T., and Nakamura, T. Serum hepatocyte growth factor levels in liver diseases: clinical implications. Hepatology, 21: 106-112, 1995.
40. Guirouilh, J., Le Bail, B., Boussarie, L., Balabaud, C., Bioulac-Sage, P., Desmouliere, A., Schuppan, D., and Rosenbaum, J. Expression of hepatocyte growth factor in human hepatocellular carcinoma. J. Hepatol., 34: 78-83, 2001.
41. Yamagamim, H., Moriyama, M., Matsumura, H., Aoki, H., Shimizu, T., Saito, T., Kaneko, M., Shioda, A., Tanaka, N., and Arakawa, Y. Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseases. Cancer (Phila.), 95: 824-834, 2002.
42. Monvoisin, A., Neaud, V., De Ledinghen, V., Dubuisson, L., Balabaud, C., Bioulac-Sage, P., Desmouliere, A., and Rosenbaum, J. Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase. J. Hepatol., 30: 511-518, 1999.
43. Gardiner-Garden, M., and Frommer, M. CpG islands in vertebrate genomes. J. Mol. Biol., 196: 261-282, 1987.